In a research letter published by Kim and Hartman in JAMA Dermatology, investigators uncovered how the COVID-19 pandemic may have impacted the incidence of in situ and invasive cutaneous melanoma. Researchers used data from 17 Surveillance, Epidemiology, and End Results registries to identify nearly 77,000 patients with primary in situ or invasive cutaneous melanoma diagnosed between January 2018 and December 2020. They then analyzed changes in the incidence rate of melanoma during that time period—taking consideration of demographic, pathologic, and racial variables—and calculated the age-adjusted incidence rates per 100,000 person-years. The investigators discovered that the incidence rates of in situ and invasive cutaneous melanoma remained stable from 2018 to 2019 but decreased in 2020, particularly among older, male, and non-Hispanic White patients. Similarly, the incidence rates of superficial spreading, T1, nonulcerated, nonmitogenic, and stage I melanomas all decreased in 2020 compared with the prior 2 years. The investigators stressed that their new findings may represent reduced skin cancer screenings and access to dermatologic care during the COVID-19 pandemic—which may have contributed to less melanoma diagnoses. In future studies, they expect to observe slight increases in thicker melanomas in 2021 to account for missed diagnoses in 2020.